Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice

• Published in: PloS one Vol. 9; no. 7; p. e101267
• Main Authors: Jump, Robin L P, Polinkovsky, Alex, Hurless, Kelly, Sitzlar, Brett, Eckart, Kevin, Tomas, Myreen, Deshpande, Abhishek, Nerandzic, Michelle M, Donskey, Curtis J
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 02.07.2014; Public Library of Science (PLoS)
• Subjects: Amino acids; Anaerobes; Analysis; Animals; Anti-Bacterial Agents - pharmacology; Antibiotic resistance; Antibiotics; Bacteria; Bacteria - metabolism; Bacteroidetes; Bioindicators; Biological markers; Biology and Life Sciences; Biomarkers; Biomarkers - metabolism; Carbohydrate metabolism; Carbohydrates; Clindamycin; Clindamycin - pharmacology; Clostridium difficile; Colonization; Feces; Female; Geriatrics; In vivo methods and tests; Infections; Infectious diseases; Inositol; Intermediates; Intestinal microflora; Intestinal Mucosa - metabolism; Intestine; Intestines - microbiology; Medicine; Medicine and Health Sciences; Metabolism; Metabolites; Metabolome - drug effects; Metabolomics; Metabolomics - methods; Mice; Microbiota; Microbiota (Symbiotic organisms); Microbiota - drug effects; Microorganisms; Model testing; Physical Sciences; Piperacillin; Polymerase chain reaction; Protein metabolism; Protein turnover; Recovery; Research and Analysis Methods; Restoration; Spores; Tazobactam; Vancomycin; Veterans; Cleveland Ohio; United States > US; Ohio
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0101267

The intestinal microbiota protect the host against enteric pathogens through a defense mechanism termed colonization resistance. Antibiotics excreted into the intestinal tract may disrupt colonization resistance and alter normal metabolic functions of the microbiota. We used a mouse model to test the hypothesis that alterations in levels of bacterial metabolites in fecal specimens could provide useful biomarkers indicating disrupted or intact colonization resistance after antibiotic treatment. To assess in vivo colonization resistance, mice were challenged with oral vancomycin-resistant Enterococcus or Clostridium difficile spores at varying time points after treatment with the lincosamide antibiotic clindamycin. For concurrent groups of antibiotic-treated mice, stool samples were analyzed using quantitative real-time polymerase chain reaction to assess changes in the microbiota and using non-targeted metabolic profiling. To assess whether the findings were applicable to another antibiotic class that suppresses intestinal anaerobes, similar experiments were conducted with piperacillin/tazobactam. Colonization resistance began to recover within 5 days and was intact by 12 days after clindamycin treatment, coinciding with the recovery bacteria from the families Lachnospiraceae and Ruminococcaceae, both part of the phylum Firmicutes. Clindamycin treatment caused marked changes in metabolites present in fecal specimens. Of 484 compounds analyzed, 146 (30%) exhibited a significant increase or decrease in concentration during clindamycin treatment followed by recovery to baseline that coincided with restoration of in vivo colonization resistance. Identified as potential biomarkers of colonization resistance, these compounds included intermediates in carbohydrate or protein metabolism that increased (pentitols, gamma-glutamyl amino acids and inositol metabolites) or decreased (pentoses, dipeptides) with clindamycin treatment. Piperacillin/tazobactam treatment caused similar alterations in the intestinal microbiota and fecal metabolites. Recovery of colonization resistance after antibiotic treatment coincided with restoration of several fecal bacterial metabolites. These metabolites could provide useful biomarkers indicating intact or disrupted colonization resistance during and after antibiotic treatment.